|Bid||62.69 x 100|
|Ask||63.80 x 100|
|Day's Range||62.35 - 63.93|
|52 Week Range||61.30 - 140.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||82.31|
Incyte Corporation announced today that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 8:40 am PDT in Las Vegas.
Incyte Corporation announces that multiple abstracts from its research and development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology annual meeting in Chicago, Illinois from June 1-5, 2018.
NEW YORK, NY / ACCESSWIRE / April 25, 2018 / The markets recent slide continued Tuesday as concerns of rising interest rates continued to plague investors. On Tuesday, the yield on the benchmark on the ...
rheumatoid arthritis drug baricitinib, Eli Lilly chairman and CEO David Ricks on an earnings call Tuesday expressed confidence in the benefit-risk profile of both doses of the treatment. The advisory panel recommended that the FDA approve the 2-mg dose of baricitinib, but not the 4-mg dose for the proposed indication based on the adequacy of the safety and benefit-risk profiles. "While we are pleased that the FDA's arthritis advisory committee supported the efficacy of both 2 mg and 4 mg of baricitinib in RA and 2 mg overall, we are disappointed that the committee did not recommend approval of the 4-mg dose," Ricks said.
Eli Lilly & Co. shares dropped nearly 3% in premarket trade Tuesday after the company's rheumatoid arthritis therapy baricitinib was recommended for Food and Drug Administration approval at the 2-mg dose, but not the 4-mg dose. Incyte Corp. , a partner on the drug, had its shares drop nearly 5% premarket. The recommendation, made by the FDA's arthritis advisory committee late Monday, was based on concerns about the 4-mg dose's safety and risks relative to its benefits.
INDIANAPOLIS, April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.
NEW YORK , April 20, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Incyte Corporation ("Incyte" ...
NEW YORK , April 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation ("Incyte" or the "Company") (NASDAQ: INCY). Such investors ...
Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...
Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.
The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug. An independent ...
NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.
NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
The S&P 500’s top gainers on April 12 were: Incyte (INCY) gained 5.3%. Micron Technology (MU) gained 4.2%. Host Marriott Financial Trust (HST) gained 4.1%. Deere & Company (DE) gained 4.1%. Discovery (DISCK) gained 3.9%. Incyte
Incyte Corporation announced today that it has scheduled its first quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 1, 2018.